Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett’s Syndrome (TREE study)

by Ysios Capital

1 year ago
leriglitazone, Rett syndrome., TREE, Minoryx Therapeutics

TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

by Ysios Capital

2 years ago
cerebral Adrenoleukodystrophy, Leriglitazone

Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European spe...

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

by Ysios Capital

Minoryx Therapeutics today announces the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukod...

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

by Minoryx Therapeutics

5 years ago
cerebral lesion, biomarker, X-ALD, leriglitazone, Minoryx

Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data.

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

by Minoryx Therapeutics

5 years ago
X-ALD, leriglitazone, Minoryx

Published data highlights therapeutic potential for all forms of X-ALD as well as other neurodegenerative and neuroinflammatory diseases

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

by Minoryx Therapeutics

6 years ago
biomarkers, Neurobiology, leriglitazone, Friedreich´s ataxia

Study demonstrates leriglitazone improves relevant disease biomarkers and ataxia resulting in clinical benefit in this orphan disease

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

by Minoryx Therapeutics

6 years ago
financing, neurodegenerative diseases, Minoryx Therapeutics, leriglitazone, biomedicine, EIB

Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that th...

Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trial

by Minoryx Therapeutics

6 years ago
pediatric, Central Nervous System, leriglitazone

Pediatric Investigational Plan (PIP) for leriglitazone in X-ALD approved by EMA, allowing to file Marketing Authorization Application (MAA) in Europe based on NEXUS